Uzbekistan, Tashkent, Jan.21 / Trend , D.Azizov /
Uzbekistan is trying to get the Hungarian Omninvest Development КFT company to investment in the creation of vaccines and biological medicine productions, state joint-stock concern Uzfarmprom said.
Uzfarmprom representatives said that Uzbek President Islam Karimov has approved an investment agreement signed in late 2009 between the republic's government and Omninvest.
According to the agreement, Omninvest Development КFT will invest in the production of a vaccine, serum and biological complex worth $100 million in 2010-2013. Also, Omnivest plans to start producing an influenza vaccine with a capacity of 12 million doses a year.
The investor should start producing pertussis, diphtheria, tetanus, anti-tubercular and typhoid vaccines in August 2012. At the moment, these vaccines and medicines are not produced at the local market and are imported.
The Hungarian company also plans to produce biological active additives, as well as establish a stem cells center, and therapy and gene therapy within the investment agreement in 2013.
According to the business plan, up to 70 percent of produced products will be exported.
The investor has established Omninvest Asia Ltd in Uzbekistan for the project implementation, which is exempt from taxes and customs payments for five years with a president's decree.
As it was reported earlier, Uzfarmprom will implement a program of modernization and technical re-equipment industry worth $26.5 million in 2007-2011.
The company intends to spend $12.4 million for the implementation of projects on modernization of production of injection, tablet and liquid medicines; $5.9 million to expand production of infusion solutions; $5.4 million to expand production of medical products.
As it was reported earlier, Singapore Beacons Pharmaceuticals and Uzfarmprom signed an agreement to build a pharmaceutical factory worth $10 million on the territory of the industrial free trade zone (SIEZ) Navoi in Uzbekistan. The new company plans to produce 40 types of drugs, including miorelaxants, as well as aspirin and vitamin C in late 2009.